指南与共识血栓与止血

ASH ISTH NHF WFH 2021 血管性血友病管理指南

ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease.
指南 / 共识 · Blood Adv · 2021-01-01

BACKGROUND: von Willebrand disease (VWD) is a common inherited bleeding disorder. Significant variability exists in management options offered to patients.…

要点

  • 对频繁复发性出血者考虑预防治疗。
  • 用去氨加压素试验指导治疗选择。
  • 大手术需设定 VWF 和因子 VIII 活性目标水平。

核心结论

  • 指南针对 VWD 管理达成 12 条推荐并列出未来研究重点。

主要发现

  • 小组就 12 条推荐达成共识并概述了未来研究优先方向。

关键数值与推荐

  • 推荐涉及频繁复发性出血的预防、去氨加压素试验确定治疗、抗血小板药与抗凝治疗的使用、大手术的 VWF 和因子 VIII 活性目标水平、小手术或侵入性操作减少出血的策略、月经过多的管理、分娩时椎管内麻醉的 VWD 管理及产后管理。

临床怎么用

  • 临床可依据指南推荐管理 VWD 患者的预防治疗、去氨加压素试验、抗血小板/抗凝决策、围手术期目标水平及月经过多和围产期管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: von Willebrand disease (VWD) is a common inherited bleeding disorder. Significant variability exists in management options offered to patients. OBJECTIVE: These evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and health care professionals in their decisions about management of VWD. METHODS: ASH, ISTH, NHF, and WFH formed a multidisciplinary guideline panel. Three patient representatives were included. The panel was balanced to minimize potential bias from conflicts of interest. The University of Kansas Outcomes and Implementation Research Unit and the McMaster Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process, including performing and updating systematic evidence reviews (through November 2019). The panel prioritized clinical questions and outcomes according to their importance to clinicians and patients. The panel used the GRADE approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 12 recommendations and outlined future research priorities. CONCLUSIONS: These guidelines make key recommendations regarding prophylaxis for frequent recurrent bleeding, desmopressin trials to determine therapy, use of antiplatelet agents and anticoagulant therapy, target VWF and factor VIII activity levels for major surgery, strategies to reduce bleeding during minor surgery or invasive procedures, management options for heavy menstrual bleeding, management of VWD in the context of neuraxial anesthesia during labor and delivery, and management in the postpartum setting.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021. PMID: 33570647. doi:10.1182/bloodadvances.2020003264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。